Operates medical centers for aesthetic and plastic surgery. Develops and markets pharmaceutical, medical, and medical technology products. Now — the numbers.
This is an established company with proven profits.
No real growth (4% a year).
If every debt were paid off today, $36.8M would still be left in the vault — a solid cushion for hard times.
The market pays 8.4× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
There is $48.7M in the vault; even if every debt were paid off, $36.8M would remain.
It pays out $1.37 per share each year — regular cash for whoever holds the stock.
The price action doesn’t yet back an upward turn. Council score: 0/10.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
As the slice kept from each sale thins out, so does the profit. Council score: 3/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.